Plain-English translation of NCT03150693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding a targeted antibody drug called to standard leukemia chemotherapy can help young adults (ages 18–39) with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) have better outcomes. Half the participants will receive standard chemotherapy alone, and the other half will receive the same chemotherapy plus this new medication. The trial is designed to see whether the medication helps people stay in remission longer and improve their overall survival.
B-cell ALL is a serious blood cancer that affects young adults. While standard chemotherapy helps many patients, some still experience cancer recurrence. This medication is being tested because early research suggests it may work better at targeting and destroying leukemia cells, potentially improving long-term survival for patients who receive it alongside standard treatment.
You likely qualify if…
You likely don't qualify if…
You will first receive standard remission induction chemotherapy to bring your leukemia into remission. After completing this initial phase, if your bone marrow shows good response, you will be randomly assigned to receive either standard follow-up chemotherapy alone or the same chemotherapy plus the new targeted antibody drug given intravenously on specific days. Throughout the trial, you will have regular bone marrow biopsies, blood tests, heart imaging, and chest X-rays to monitor your health and how well the treatment is working. The entire treatment process typically lasts several months to over a year, with visits scheduled according to your treatment plan.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States